Chinese media is reporting a breakthrough in HIV prevention and treatment in the form of a new broad-spectrum antibody drug called “BiIA-SG”.
Developed by the Hong Kong University AIDS Research Institute, director, Professor Chen Zhiwei held a press conference ast week to announce they have successfully used genetic engineering technology to develop an innovative broad-spectrum antibody drug “BiIA-SG” for AIDS prevention and immunotherapy.
Zhiwei called BilA-SG “one of the most potent and effective antibody drugs” for HIV prevention and treatment.
Research from his team indicates that mice were not only protected from contracting the disease, but 42 percent of the HIV infected mice had an “undetectable level” of the virus for at least four weeks and inhibited HIV in the body within 3 months, effectively reducing the amount of virus.
The greatest challenge in HIV prevention and treatment is that the disease grows and mutates rapidly.
Zhiwei found that BiIA-SG prevented 124 subtypes of HIV virus from infecting mice on treatment, with the preventative antibodies maintained in the body for a week.
This would revolutionise HIV/AIDs treatments such as PrEP where people have to take the drug on a daily basis.